CN101603030B - 一种体外扩增调节性t细胞的方法 - Google Patents
一种体外扩增调节性t细胞的方法 Download PDFInfo
- Publication number
- CN101603030B CN101603030B CN2009100317773A CN200910031777A CN101603030B CN 101603030 B CN101603030 B CN 101603030B CN 2009100317773 A CN2009100317773 A CN 2009100317773A CN 200910031777 A CN200910031777 A CN 200910031777A CN 101603030 B CN101603030 B CN 101603030B
- Authority
- CN
- China
- Prior art keywords
- cells
- regulatory
- cell
- tgf
- beta
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000338 in vitro Methods 0.000 title claims abstract description 27
- 230000003321 amplification Effects 0.000 title claims abstract description 19
- 238000003199 nucleic acid amplification method Methods 0.000 title claims abstract description 19
- 238000000034 method Methods 0.000 title claims abstract description 18
- 210000003289 regulatory T cell Anatomy 0.000 title claims description 91
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 62
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims abstract description 61
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims abstract description 61
- 229960002930 sirolimus Drugs 0.000 claims abstract description 61
- 210000004027 cell Anatomy 0.000 claims abstract description 52
- 230000000638 stimulation Effects 0.000 claims description 16
- 230000006698 induction Effects 0.000 claims description 15
- 210000004369 blood Anatomy 0.000 claims description 12
- 239000008280 blood Substances 0.000 claims description 12
- 239000011324 bead Substances 0.000 claims description 10
- 230000000735 allogeneic effect Effects 0.000 claims description 9
- 238000012258 culturing Methods 0.000 claims description 9
- 210000004443 dendritic cell Anatomy 0.000 claims description 9
- 239000000427 antigen Substances 0.000 claims description 8
- 102000036639 antigens Human genes 0.000 claims description 8
- 108091007433 antigens Proteins 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 102100027207 CD27 antigen Human genes 0.000 claims description 7
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 7
- 239000000411 inducer Substances 0.000 claims description 7
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 6
- 239000012980 RPMI-1640 medium Substances 0.000 claims description 6
- 238000004113 cell culture Methods 0.000 claims description 6
- 239000002609 medium Substances 0.000 claims description 6
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 claims description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 claims description 6
- 108010001857 Cell Surface Receptors Proteins 0.000 claims description 5
- 239000001963 growth medium Substances 0.000 claims description 5
- 238000000926 separation method Methods 0.000 claims description 5
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 4
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 4
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 claims description 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 3
- 229930182555 Penicillin Natural products 0.000 claims description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 3
- 230000010100 anticoagulation Effects 0.000 claims description 3
- 229960002989 glutamic acid Drugs 0.000 claims description 3
- 229960002897 heparin Drugs 0.000 claims description 3
- 229920000669 heparin Polymers 0.000 claims description 3
- MAYUCBCSAVDUKG-UHFFFAOYSA-N orthoacetic acid Chemical compound CC(O)(O)O MAYUCBCSAVDUKG-UHFFFAOYSA-N 0.000 claims description 3
- 229940049954 penicillin Drugs 0.000 claims description 3
- 229940054269 sodium pyruvate Drugs 0.000 claims description 3
- 229960005322 streptomycin Drugs 0.000 claims description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 2
- ZCWSUIQMOPJBCK-UHFFFAOYSA-N C(C)S(=O)(=O)O.C(C)ON1CCNCC1 Chemical compound C(C)S(=O)(=O)O.C(C)ON1CCNCC1 ZCWSUIQMOPJBCK-UHFFFAOYSA-N 0.000 claims description 2
- 229940024606 amino acid Drugs 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 230000010261 cell growth Effects 0.000 claims description 2
- 239000012091 fetal bovine serum Substances 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 230000004936 stimulating effect Effects 0.000 claims description 2
- 102000006240 membrane receptors Human genes 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 abstract description 40
- 108090001012 Transforming Growth Factor beta Proteins 0.000 abstract description 40
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 abstract description 40
- 210000000056 organ Anatomy 0.000 abstract description 7
- 208000023275 Autoimmune disease Diseases 0.000 abstract description 6
- 230000004069 differentiation Effects 0.000 abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
- 230000008901 benefit Effects 0.000 abstract description 4
- 206010061218 Inflammation Diseases 0.000 abstract description 3
- 230000007547 defect Effects 0.000 abstract description 3
- 230000036039 immunity Effects 0.000 abstract description 3
- 230000004054 inflammatory process Effects 0.000 abstract description 3
- 230000008629 immune suppression Effects 0.000 abstract description 2
- 238000002513 implantation Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 210000002501 natural regulatory T cell Anatomy 0.000 description 17
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 14
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 14
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 14
- 210000002602 induced regulatory T cell Anatomy 0.000 description 14
- 238000002054 transplantation Methods 0.000 description 13
- 230000006870 function Effects 0.000 description 12
- 108091008874 T cell receptors Proteins 0.000 description 9
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 239000003018 immunosuppressive agent Substances 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 210000000068 Th17 cell Anatomy 0.000 description 7
- 230000001506 immunosuppresive effect Effects 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 208000009329 Graft vs Host Disease Diseases 0.000 description 6
- 230000006907 apoptotic process Effects 0.000 description 6
- 208000024908 graft versus host disease Diseases 0.000 description 6
- 230000001939 inductive effect Effects 0.000 description 6
- 102000013691 Interleukin-17 Human genes 0.000 description 5
- 108050003558 Interleukin-17 Proteins 0.000 description 5
- 230000006058 immune tolerance Effects 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- 102000004889 Interleukin-6 Human genes 0.000 description 4
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 210000001541 thymus gland Anatomy 0.000 description 4
- 102000000844 Cell Surface Receptors Human genes 0.000 description 3
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 3
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 210000003162 effector t lymphocyte Anatomy 0.000 description 3
- 239000005090 green fluorescent protein Substances 0.000 description 3
- 229960003444 immunosuppressant agent Drugs 0.000 description 3
- 230000001861 immunosuppressant effect Effects 0.000 description 3
- 229940125721 immunosuppressive agent Drugs 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 2
- 229940045513 CTLA4 antagonist Drugs 0.000 description 2
- 102100035716 Glycophorin-A Human genes 0.000 description 2
- 102000006354 HLA-DR Antigens Human genes 0.000 description 2
- 108010058597 HLA-DR Antigens Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101001046687 Homo sapiens Integrin alpha-E Proteins 0.000 description 2
- 206010062016 Immunosuppression Diseases 0.000 description 2
- 102100022341 Integrin alpha-E Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 238000011579 SCID mouse model Methods 0.000 description 2
- 230000006052 T cell proliferation Effects 0.000 description 2
- 206010052779 Transplant rejections Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940124589 immunosuppressive drug Drugs 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 102000049320 CD36 Human genes 0.000 description 1
- 108010045374 CD36 Antigens Proteins 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 206010068051 Chimerism Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 108091005250 Glycophorins Proteins 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 1
- 101001074244 Homo sapiens Glycophorin-A Proteins 0.000 description 1
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
- 101000979342 Homo sapiens Nuclear factor NF-kappa-B p105 subunit Proteins 0.000 description 1
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- 206010025327 Lymphopenia Diseases 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 102100025751 Mothers against decapentaplegic homolog 2 Human genes 0.000 description 1
- 101710143123 Mothers against decapentaplegic homolog 2 Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 description 1
- 229940079156 Proteasome inhibitor Drugs 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010038540 Renal tubular necrosis Diseases 0.000 description 1
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 1
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Natural products O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000024340 acute graft versus host disease Diseases 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000004940 costimulation Effects 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 230000002435 cytoreductive effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000010212 intracellular staining Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000011694 lewis rat Methods 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000011418 maintenance treatment Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000003207 proteasome inhibitor Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000007727 signaling mechanism Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 230000003614 tolerogenic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Images
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009100317773A CN101603030B (zh) | 2009-07-14 | 2009-07-14 | 一种体外扩增调节性t细胞的方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009100317773A CN101603030B (zh) | 2009-07-14 | 2009-07-14 | 一种体外扩增调节性t细胞的方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101603030A CN101603030A (zh) | 2009-12-16 |
CN101603030B true CN101603030B (zh) | 2011-05-25 |
Family
ID=41468929
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2009100317773A Expired - Fee Related CN101603030B (zh) | 2009-07-14 | 2009-07-14 | 一种体外扩增调节性t细胞的方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101603030B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103555667A (zh) * | 2013-10-17 | 2014-02-05 | 中国人民解放军第三军医大学 | 利用重组人IL-26分选小鼠Th17细胞的方法 |
CN104357389A (zh) * | 2014-10-15 | 2015-02-18 | 湖南赛诺生物科技有限责任公司 | 一种改良的人脐血来源调节性t细胞扩增培养基及其使用方法 |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102062774B (zh) * | 2009-11-13 | 2013-08-21 | 程小星 | 检测结核病治疗效果的试剂盒 |
CN104031880A (zh) * | 2014-06-24 | 2014-09-10 | 南昌大学 | 一种体外诱导记忆性b细胞转化为浆细胞的制备方法 |
CN104278012B (zh) * | 2014-10-11 | 2016-11-23 | 湖南赛诺生物科技股份有限公司 | 一种成人调节性t细胞体外扩增培养基及其使用方法 |
CN105483083B (zh) * | 2016-01-20 | 2018-10-23 | 北京医明佳和生物科技有限公司 | 双阴性t细胞的转化扩增方法 |
CN106244539A (zh) * | 2016-08-31 | 2016-12-21 | 深圳中山生殖与遗传研究所 | 用于从幼稚t细胞诱导扩增调节性t细胞的试剂盒 |
CN106399240A (zh) * | 2016-08-31 | 2017-02-15 | 深圳中山生殖与遗传研究所 | 一种优化的从幼稚t细胞诱导扩增调节性t细胞的方法 |
WO2018106885A1 (en) | 2016-12-07 | 2018-06-14 | East Carolina University | Compositions and methods for in vitro cultivation and/or expansion of regulatory t cells |
CN107519202A (zh) * | 2017-06-20 | 2017-12-29 | 中山大学附属第三医院 | 一种调节性t细胞的制备方法及其应用 |
CN107349219B (zh) * | 2017-07-25 | 2020-07-14 | 中南大学湘雅二医院 | 调节性t细胞在制备治疗免疫糖尿病药物中的应用、及其扩培液和扩培方法 |
CN108004208A (zh) * | 2017-12-01 | 2018-05-08 | 南京爱瑞生物科技有限公司 | 一种体外诱导抗原特异性t细胞的方法 |
CN108060129A (zh) * | 2017-12-11 | 2018-05-22 | 上海药明生物技术有限公司 | 调节性t细胞体外扩增方法 |
CN108546678A (zh) * | 2018-04-19 | 2018-09-18 | 王文娟 | 一种人外周血Treg细胞的体外分离扩增方法及其应用 |
CN109136182A (zh) * | 2018-09-17 | 2019-01-04 | 鲁勇 | 一种极化和扩增cd4+t细胞的方法及组合物及在治愈表达特异性抗原的肿瘤中的应用 |
CN110846276A (zh) * | 2019-12-04 | 2020-02-28 | 四川大学华西医院 | 一种原代调节性t细胞体外扩增体系及扩增方法 |
CN111593023A (zh) * | 2020-01-14 | 2020-08-28 | 河南省银丰生物工程技术有限公司 | 一种T-reg细胞的体外培养方法 |
CN112852731A (zh) * | 2021-03-23 | 2021-05-28 | 细胞谷(南京)生物科技有限公司 | 一种体外诱导造血干细胞向调节性t细胞分化的方法 |
-
2009
- 2009-07-14 CN CN2009100317773A patent/CN101603030B/zh not_active Expired - Fee Related
Non-Patent Citations (3)
Title |
---|
Jeroen J. A. Coenen等.Rapamycin, and not cyclosporin A, preserves the highly suppressive CD27+ subset of human CD4+CD25+ regulatory T cells,.《BLOOD》.2006,第107卷(第3期),1018-1023. * |
史艳侠等.CD4+CD25+调节性T细胞的体外扩增.《中山大学学报(医学科学版)》.2008,第29卷(第6期),664-669. * |
戴振鹏等.人CD4+CD25+调节性T细胞系的建立与功能分析.《分子与细胞免疫学》.2003,第19卷(第1期),5-8. * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103555667A (zh) * | 2013-10-17 | 2014-02-05 | 中国人民解放军第三军医大学 | 利用重组人IL-26分选小鼠Th17细胞的方法 |
CN103555667B (zh) * | 2013-10-17 | 2015-06-03 | 中国人民解放军第三军医大学 | 利用重组人IL-26分选小鼠Th17细胞的方法 |
CN104357389A (zh) * | 2014-10-15 | 2015-02-18 | 湖南赛诺生物科技有限责任公司 | 一种改良的人脐血来源调节性t细胞扩增培养基及其使用方法 |
Also Published As
Publication number | Publication date |
---|---|
CN101603030A (zh) | 2009-12-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101603030B (zh) | 一种体外扩增调节性t细胞的方法 | |
US20210371820A1 (en) | Method for amplifying antigen-specific regulatory t cells in vitro | |
EP1409650B1 (en) | Ex-vivo isolated cd25+cd4+ t cells with immunosuppressive activity and uses thereof | |
US6759035B2 (en) | Method to prevent graft rejection using TGF-beta to induce T suppressor cells | |
JP2016190868A (ja) | 同種異系細胞治療:ミラー効果 | |
EP0966523A1 (en) | Method for the production of selected lymphocytes | |
JP2007500217A5 (zh) | ||
AU1077801A (en) | Suppressor cells for prevention and treatment of immune responses in transplantation | |
US20030134415A1 (en) | Th1 cell adoptive immunotherapy | |
JP2004529631A (ja) | ヒト血液由来のcd4+cd25+調節t細胞 | |
US8603815B2 (en) | CD4+ CD25− T cells and Tr1-like regulatory T cells | |
EP2689009A1 (en) | Method for using regulatory t cells in therapy | |
WO2007131575A1 (en) | Tolerogenic dendritic cells, method for their production and uses thereof | |
US20030134341A1 (en) | Th1 cell adoptive immunotherapy | |
JP6283347B2 (ja) | 成熟樹状細胞集団の製造方法 | |
US20030194395A1 (en) | Th1 cell adoptive immunotherapy | |
CN112852731A (zh) | 一种体外诱导造血干细胞向调节性t细胞分化的方法 | |
WO2021123927A1 (en) | Method of generation of lympho-myeloid niches | |
CN109535241B (zh) | Dc-cik共培养细胞及其制备方法、致敏抗原和应用 | |
JP2024512814A (ja) | 臍帯血から得られた制御性t細胞を培養することによって制御性t細胞を製造する方法 | |
WO2010129770A1 (en) | Methods for expanding human t regulatory cells and uses of same | |
JP5717116B2 (ja) | 抗原特異的ヒトTh17細胞を調整する方法 | |
CN113825832A (zh) | 一种体外诱导CD4+Foxp3+CD69+Treg的扩增方法及其用途 | |
Zhao et al. | Human Cord Blood Stem Cell-Modulated Regulatory T Lymphocytes Reverse the | |
Gregori et al. | of Human Natural and Adaptive Regulatory T Cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: ZHANG FENG WANG XUEHAO LI GUOQIANG Free format text: FORMER OWNER: ZHANG FENG WANG XUEHAO |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20110815 Address after: 210036 Jinling century garden, Hanzhoung Avenue, Gulou District, Jiangsu, 168-502, Nanjing Co-patentee after: Zhang Feng Patentee after: Lv Ling Co-patentee after: Wang Xuehao Co-patentee after: Li Guoqiang Address before: 210036 Jinling century garden, Hanzhoung Avenue, Gulou District, Jiangsu, 168-502, Nanjing Co-patentee before: Zhang Feng Patentee before: Lv Ling Co-patentee before: Wang Xuehao |
|
ASS | Succession or assignment of patent right |
Free format text: FORMER OWNER: ZHANG FENG WANG XUEHAO LI GUOQIANG Effective date: 20120522 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20120522 Address after: 210036 Jinling century garden, Hanzhoung Avenue, Gulou District, Jiangsu, 168-502, Nanjing Patentee after: Lv Ling Address before: 210036 Jinling century garden, Hanzhoung Avenue, Gulou District, Jiangsu, 168-502, Nanjing Co-patentee before: Zhang Feng Patentee before: Lv Ling Co-patentee before: Wang Xuehao Co-patentee before: Li Guoqiang |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110525 Termination date: 20180714 |
|
CF01 | Termination of patent right due to non-payment of annual fee |